{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
INN:bexotegrast [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ACHIRAL)
ITAMELINE, a tetrahydropyridine-oxime, is a long-lasting cholinomimetic agent. It is cleaved in vivo to form an active metabolite, RU 35963, a muscarinic receptor agonist that is nonselective with respect to receptor subtypes.
Status:
Investigational
Source:
NCT00635804: Phase 1 Interventional Completed Hepatitis C
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MK-3281 is a potent and orally bioavailable inhibitor of HCV NS5B polymerase which combined excellent cell-based potency with good pharmacokinetic properties in preclinical species. MK-3281 was efficacious in the chimeric mouse model of HCV infection.
Status:
Investigational
Source:
INN:betovumeline [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04630756: Phase 1/Phase 2 Interventional Active, not recruiting Advanced Haematological Malignancies
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04341454: Phase 3 Interventional Completed Acute Gastritis
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03556319: Not Applicable Interventional Completed Older Adults
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01097408: Phase 1 Interventional Completed Healthy
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
A-689 (AZD-7295) was the lead compound from Arrow Therapeutics' second series of hepatitis C virus (HCV) NS5a inhibitors. AZD-7295 is a selective inhibitor of HCV NS5A within vitroantiviral activity of 7nM and 1.24mM against HCV genotype1b and 1a replicons respectively, with significant liver concentrationin preclinical studies. AZD-7295 was well tolerated at repeated doses ofup to 700 mg daily. AZD-7295 shows potent antiviral activity ingenotype 1b patients. Genotype 1a and genotype 3 patients showedno antiviral effects.
Status:
Investigational
Source:
NCT02684591: Phase 2 Interventional Completed Nonalcoholic Fatty Liver Disease
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
